BioInvent International
23.11.2021 17:38:03 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV)
Friday, December 17 at 1 pm ET (7 pm CET)
BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key opinion leader (KOL) webinar on BI-1206, a potential treatment for non-Hodgkin's lymphoma and solid tumors, on Friday, December 17, 2021 at 1:00pmET/7:00pmCET.
The webcast will feature KOL Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current treatment landscape and unmet medical need in treating patients with non-Hodgkin's lymphoma (NHL) and Mantle Cell Lymphoma (MCL).
BioInvent's management team will provide an update on the ongoing BI-1206 clinical studies for the treatment of non-Hodgkin's lymphoma and solid tumors, including an overview of the NHL data presented at ASH on December 11.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
BI-1206 is a monoclonal antibody that selectivity binds to FcγRIIB (CD32B). By blocking FcγRIIB, BI-1206 can recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of NHL. In addition, BI-1206 has the potential to reduce resistance to PD-1 immune checkpoint blockade, providing a new way to enhance anti-tumor immune responses in patients with solid tumors.
To register for the event, please click here.
Luhua (Michael) Wang, M.D. is a Professor in the department of Lymphoma & Myeloma at MD Anderson. Dr. Wang obtained his M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. He completed his clinical training as a resident at Norwalk Hospital, Norwalk, Connecticut, and as a Fellow in Oncology and in Hematology at MD Anderson.
Dr. Wang has published more than 150 peer-reviewed papers and presented his work at meetings nationally and internationally. He is the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, he has focused on preclinical and clinical research and established an MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. Dr. Wang has pioneered the work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib and acalabrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of these patients. His work has been published in the most prestigious medical journals such as the NEJM and the Lancet. He is currently the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
About BioInvent
BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Attachments
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674388/BioInvent-Hosting-Key-Opinion-Leader-Webinar-on-BI-1206
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI and Coppercore Inc. Announce Tokenization of High-Grade Copper Resources into Coppercoin(TM)31.3.2026 15:15:00 CEST | Press release
$100 Million in Initial Coppercoin™ Issuance to Set Industry Standard in Tokenized Copper PHILADELPHIA, PA / ACCESS Newswire / March 31, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, and Coppercore Inc. ("Coppercore") today announced the closing of a definitive agreement to digitize and tokenize significant copper resources. The transaction enables Datavault AI to deploy its patented IDE®, DataScore®, and DataValue® blockchain tokenization platform to create Coppercoin™ digital tokens representing pro-rata ownership interests in the underlying in-ground resources. The initial program targets the minting of $100 million or more in Digital Copper Tokens. Coppercoin™ tokens are structured such that each token corresponds to five pounds of underlying high-grade copper resources, with pricing directly linked to the COMEX copper benchmark on a pe
AccessPay Accelerates Growth With Majority Investment From Leading Software Investor, Accel-KKR31.3.2026 10:00:00 CEST | Press release
Financial backing enables AccessPay to scale services for enterprise clients and drive innovation in finance operations MANCHESTER, UK / ACCESS Newswire / March 31, 2026 / AccessPay, a leading bank integration and payment automation provider, has secured a majority investment from Accel-KKR, a prominent global private equity firm specialising in enterprise technology and software companies. The investment is expected to enable AccessPay to fuel the next phase of growth and further its ambition to become a world-class SaaS business driving innovation in the office of the CFO. The investment also opens the door for AccessPay to pursue growth via strategic acquisitions. The office of the CFO faces an increasingly testing operating environment. Alongside cost pressures, increased cyber threats, and a volatile geopolitical climate, AI is fundamentally rewiring finance operating practices. A global McKinsey survey of CFOs from late 2025 reported that 44% of survey respondents had identified
The World's First Agentic CMS Just Got Smarter: Kontent.ai Launches Expert Agents31.3.2026 09:00:00 CEST | Press release
Kontent.ai, the team behind the world's first Agentic CMS, today announced the launch of Expert Agents: purpose-built AI agents that bring deep, specialized intelligence to the content operations teams manage every day. Expert Agents work continuously across content workflows, handling everything that doesn't require human judgment. They can be configured by anyone using simple natural language prompts. BRNO, CZ / ACCESS Newswire / March 31, 2026 / Expert Agents help organizations move faster than ever before, augmenting teams without adding headcount, accelerating campaign launches across markets, improving content performance at scale, and reducing regulatory and compliance risk across even the largest content inventories. The launch marks the next step in Kontent.ai's Agentic CMS vision: a platform where AI agents are embedded directly into the operational layer of content management. At its core, the Agentic CMS combines two layers of intelligence: the Main Agent, which lets teams
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy30.3.2026 16:55:00 CEST | Press release
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development. Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate
CORRECTION: Mandela Dollar ("MUSD") Announced to Promote Mandela's Legacy of Financial Inclusion for Underserved Communities Across the World30.3.2026 16:25:00 CEST | Press release
This Press Release updates the previous version that had incorrect information Datavault AI Inc., Mandela Dlamini & Manaway L.L.C., and Unity Reserve Holdings L.L.C. Launch MUSD Stablecoin to Advance Financial Inclusion and Honor Nelson Mandela's Legacy PHILADELPHIA, PA / ACCESS Newswire / March 30, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset ("RWA") tokenization technologies, Mandela Dlamini & Manaway L.L.C., a Wyoming, USA-based entity ("MDM LLC") dedicated to advancing Nelson Mandela's vision of equality, dignity, and economic empowerment, and Unity Reserve Holdings L.L.C. ("Unity Reserve"), today announced the official launch of Mandela Dollar ("MUSD"), a new USD-pegged stablecoin designed to promote financial inclusion for underserved communities globally. MUSD is designed to serve as a transparent, secure, and accessible digital dollar built on blockchain technology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom